Specifically, JAK2 V617F in myeloproliferative disorders8, 9 and PML‐RARA fusions in acute promyelocytic leukemia (APL)10, 11 are well‐described genetic alterations associated with marked thrombotic risk. The gene discussed is JAK2; the disease is acute promyelocytic leukemia.